| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 252.27 | -51 |
| Intrinsic value (DCF) | 583183.26 | 113422 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.